(Q38808628)

6 September 2017

Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell (English)

1 reference

6 September 2017

neoplastic stem cells

1 reference

1 reference

Zhidong Wang

1

1 reference

6 September 2017

Jian Sun

2

1 reference

6 September 2017

Yeqian Feng

3

1 reference

6 September 2017

Xiaocai Tian

4

1 reference

6 September 2017

Bin Wang

5

1 reference

6 September 2017

Yong Zhou

6

1 reference

6 September 2017

14 April 2016

1 reference

6 September 2017

1 reference

6 September 2017

37

1 reference

6 September 2017

7

1 reference

6 September 2017

8515-8528

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-016-5016-z

6 September 2017

0 references

cites work

Cancer treatment and survivorship statistics, 2014

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

One hundred years of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

New driver mutations in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Chipping away at the lung cancer genome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Epidemiology of Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Cancer treatment and survivorship statistics, 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

21 January 2018

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Lung cancer: epidemiology, etiology, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Epidemiology of lung cancer: smoking, secondhand smoke, and genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

21 January 2018

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Chemokines: roles in leukocyte development, trafficking, and effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Chemokines in tumor development and progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Chemokines as mediators of tumor angiogenesis and neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Chemokines in tumor-associated angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Chemokines: a new classification system and their role in immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Homeostatic chemokine receptors and organ-specific metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Involvement of chemokine receptors in breast cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Diversity and Inter-Connections in the CXCR4 Chemokine Receptor/Ligand Family: Molecular Perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Molecular cloning and structure of a pre-B-cell growth-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Regulation of CXCR4 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

beta-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between beta-arrestin and CXCR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Wnt signaling regulates intermediate precursor production in the postnatal dentate gyrus by regulating CXCR4 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Regulation of CXCL12 expression by canonical Wnt signaling in bone marrow stromal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Wnt5a promotes ewing sarcoma cell migration through upregulating CXCR4 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

HGF upregulates CXCR4 expression in gliomas via NF-kappaB: implications for glioma cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast carcinoma cells, and role of HDACs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

NF-kappaB in mammary gland development and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

TNF-alpha mediates SDF-1 alpha-induced NF-kappa B activation and cytotoxic effects in primary astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Impaired chemokine-induced migration during T-cell development in the absence of Jak 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of the G protein-coupled receptor CXCR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine receptor CXCR4 through YY1 and impairs CXCR4/CXCL12 (SDF-1alpha)-mediated breast cancer cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

HDAC3 selectively represses CREB3-mediated transcription and migration of metastatic breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Vesnarinone downregulates CXCR4 expression via upregulation of Krüppel-like factor 2 in oral cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Functions of CXCL12 and CXCR4 in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Close correlation between CXCR4 and VEGF expression and frequent CXCR7 expression in rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Cancer and the chemokine network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

The chemokine system and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

The role of chemokine receptor CXCR4 in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCR4 over-expression and survival in cancer: a system review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Clinicopathological significance of CXCR4 in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCR4 regulates migration of lung alveolar epithelial cells through activation of Rac1 and matrix metalloproteinase-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Stromal cell-derived factor-1 enhances motility and integrin up-regulation through CXCR4, ERK and NF-kappaB-dependent pathway in human lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCR4, but not CXCR7, discriminates metastatic behavior in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Characterization of a murine model of metastatic human non-small cell lung cancer and effect of CXCR4 inhibition on the growth of metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Tumor metastasis: molecular insights and evolving paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Co-evolution of tumor cells and their microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Hallmarks of cancer: interactions with the tumor stroma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Distribution of distant metastases from newly diagnosed non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Dissemination and growth of cancer cells in metastatic sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Down-regulation of CXCL12 by DNA hypermethylation and its involvement in gastric cancer metastatic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Evaluation of protein expression and DNA methylation profiles detected by pyrosequencing in invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

The SDF-1/CXCL 12/CXCR4 biological axis in non-small cell lung cancer metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Lung cancer stem cells and implications for future therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Cancer stem cells in lung cancer: Evidence and controversies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

The cancer stem-cell hypothesis: its emerging role in lung cancer biology and its relevance for future therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Self-renewal and solid-tumor stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

The cancer stem cell: premises, promises and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Lung cancer stem cells as a target for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Stem cell factor receptor/c-Kit: from basic science to clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Diverse Targets of β-Catenin during the Epithelial-Mesenchymal Transition Define Cancer Stem Cells and Predict Disease Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Inhibition of CK2α down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCR4 positive cells from Lewis lung carcinoma cell line have cancer metastatic stem cell characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Differential effects of drugs targeting cancer stem cell (CSC) and non-CSC populations on lung primary tumors and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+ Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Development of novel CXCR4-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Potential of CXCR4 antagonists for the treatment of metastatic lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Lung cancer stem cells: progress and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCR4 inhibitors: tumor vasculature and therapeutic challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Development of a unique small molecule modulator of CXCR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Studying the binding interactions of allosteric agonists and antagonists of the CXCR4 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Reprogramming using microRNA-302 improves drug sensitivity in hepatocellular carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12/CXCR4 axis: role in non-small cell lung cancer tumor proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Discovery of small molecule CXCR4 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

G-protein-coupled receptors and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Concise review: Emerging concepts in clinical targeting of cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

The bicyclam AMD3100 story

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/β-catenin signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

MiR-451 suppresses cell proliferation and metastasis in A549 lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

c-Src/Histone Deacetylase 3 Interaction Is Crucial for Hepatocyte Growth Factor Dependent Decrease of CXCR4 Expression in Highly Invasive Breast Tumor Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-5016-Z

A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells

21 January 2018

1 reference

12 December 2020

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

1 reference

12 December 2020

CXCR4 and CXCL12 immunoreactivities differentiate primary non-small-cell lung cancer with or without brain metastases

1 reference

12 December 2020

CXCL12 and ADAM23 hypermethylation are associated with advanced breast cancers

1 reference

12 December 2020

Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review

1 reference

12 December 2020

IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer

1 reference

12 December 2020

GnRH participates in the self-renewal of A549-derived lung cancer stem-like cells through upregulation of the JNK signaling pathway

1 reference

12 December 2020

High-level C-X-C chemokine receptor type 4 expression correlates with brain-specific metastasis following complete resection of non-small cell lung cancer

1 reference

12 December 2020

Inhibition of angiogenesis, fibrosis and thrombosis by tetramethylpyrazine: mechanisms contributing to the SDF-1/CXCR4 axis

1 reference

12 December 2020

Side population cells separated from A549 lung cancer cell line possess cancer stem cell-like properties and inhibition of autophagy potentiates the cytotoxic effect of cisplatin

1 reference

12 December 2020

A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer

1 reference

12 December 2020

Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis

1 reference

12 December 2020

The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells

1 reference

12 December 2020

10.1007/S13277-016-5016-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

0 references

1 reference